The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Small nasal polyps can be harmless, but if a nasal polyp blocks the sinuses or airway, it can lead to infections, difficulty ...

For people with allergies, ongoing exposure to triggers may create a cycle of inflammation that contributes to polyp ...

which found that treatment with Fasenra achieved a statistically significant improvement in the endoscopic total nasal polyp score and nasal blockage score compared to placebo, in patients with ...

Study participants were randomly assigned tezepelumab subcutaneous injection or placebo. The co-primary endpoints were change from baseline in total nasal polyp size (measured by endoscopic total ...

Both trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score at 52 weeks and a change from baseline in mean nasal obstruction score from weeks 49 to 52.

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps. Chronic rhinosinusitis is a disorder characterised by ...